GOSS
Gossamer Bio, Inc.$0.20+0.00 (+0.35%)Prev Close$0.20·MCap$81.8M·P/E—·Vol1.35M·Yield—
▲
Buys (12M)
1
$50.0K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$50.0K
●
Active Insiders
1
last 12 mo
Over the past 12 months, insider activity at Gossamer Bio, Inc. (GOSS) has been exclusively buying, with 1 insider purchase totaling $50.0K and 0 insider sales totaling $0.00. The most recent insider transaction was by Milligan Sandra (Director), who purchased $50.0K worth of shares on Aug 20, 2025. Gossamer Bio, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $81.8M.
GOSS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 20, 2025 | Milligan Sandra | Director | Buy | 26,050 | $1.92 | $50.0K | 58,050+81% |
| Jun 25, 2024 | Aranda Richard | Chief Medical Officer | Sell | 1,908 | $0.66 | $1.3K | 196,891 |
| Jun 24, 2024 | Hasnain Faheem | President & CEO | Buy | 372,000 | $0.67 | $250.3K | 5,408,073 |
| Jun 20, 2024 | Giraudo Bryan | COO/CFO | Buy | 100,000 | $0.59 | $59.1K | 480,010+26% |
| Jun 20, 2024 | Smith Robert Paul JR | Chief Commercial Officer | Buy | 25,000 | $0.60 | $15.1K | 25,000 |
| Mar 28, 2024 | Christian Waage | EVP, Tech Ops and Admin | Sell | 6,430 | $1.16 | $7.4K | 585,934 |
| Mar 28, 2024 | Giraudo Bryan | COO/CFO | Sell | 6,430 | $1.16 | $7.4K | 92,737 |
| Mar 28, 2024 | Hasnain Faheem | President & CEO | Sell | 23,172 | $1.16 | $26.8K | 120,293 |
| Mar 19, 2024 | Aranda Richard | Chief Medical Officer | Sell | 4,018 | $1.33 | $5.3K | 198,799 |
| Mar 19, 2024 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,018 | $1.33 | $5.3K | 49,833 |
| Nov 17, 2023 | Milligan Sandra | Director | Buy | 32,000 | $0.79 | $25.2K | 32,000 |
| Nov 14, 2023 | Giraudo Bryan | COO/CFO | Buy | 200,000 | $0.56 | $112.9K | 380,010+111% |
| Jun 26, 2023 | Aranda Richard | Chief Medical Officer | Sell | 1,814 | $1.29 | $2.3K | 197,574 |
| Apr 5, 2023 | Giraudo Bryan | COO/CFO | Buy | 55,000 | $1.02 | $56.1K | 125,990+77% |
| Mar 22, 2023 | Christian Waage | EVP, Tech Ops and Admin | Buy | 18,500 | $1.20 | $22.1K | 32,388+133% |
| Mar 22, 2023 | Giraudo Bryan | COO/CFO | Buy | 50,000 | $0.97 | $48.4K | 70,990+238% |
| Mar 22, 2023 | Hasnain Faheem | President & CEO | Buy | 878,572 | $1.14 | $1.00M | 4,495,897 |
| Mar 20, 2023 | Aranda Richard | Chief Medical Officer | Sell | 7,563 | $1.10 | $8.3K | 199,388 |
| Mar 20, 2023 | Carter Laura | Chief Scientific Officer | Sell | 6,029 | $1.10 | $6.6K | 76,263 |
| Mar 20, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 7,564 | $1.10 | $8.3K | 53,851 |
| Oct 25, 2022 | Aranda Richard | Chief Medical Officer | Sell | 4,757 | $12.07 | $57.4K | 205,430 |
| Oct 25, 2022 | Carter Laura | Chief Scientific Officer | Sell | 4,876 | $12.07 | $58.9K | 82,292 |
| Oct 25, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,757 | $12.07 | $57.4K | 61,415 |
| Jul 15, 2022 | Carter Laura | Chief Scientific Officer | Buy | 6,934 | $7.21 | $50.0K | 87,168 |
| Jul 15, 2022 | Christian Waage | EVP, Tech Ops and Admin | Buy | 6,934 | $7.21 | $50.0K | 13,888+100% |
| Jul 15, 2022 | Giraudo Bryan | COO/CFO | Buy | 13,869 | $7.21 | $100.0K | 20,990+195% |
| Jul 15, 2022 | Hasnain Faheem | President & CEO | Buy | 138,696 | $7.21 | $1000.0K | 3,617,325 |
| Jul 5, 2022 | Carter Laura | Chief Scientific Officer | Sell | 8,808 | $8.25 | $72.6K | 80,234 |
| Jun 23, 2022 | Aranda Richard | Chief Medical Officer | Sell | 1,778 | $6.88 | $12.2K | 209,897 |
| May 5, 2022 | Carter Laura | Chief Scientific Officer | Sell | 1,262 | $7.20 | $9.1K | 89,042 |
| Mar 24, 2022 | Giraudo Bryan | COO/CFO | Sell | 10,722 | $8.91 | $95.6K | 99,167 |
| Mar 24, 2022 | Christian Waage | EVP, Tech Ops and Admin | Sell | 10,722 | $8.91 | $95.6K | 579,008 |
| Mar 24, 2022 | Hasnain Faheem | President & CEO | Sell | 19,035 | $8.91 | $169.7K | 143,465 |
| Mar 17, 2022 | Aranda Richard | Chief Medical Officer | Sell | 6,278 | $8.28 | $52.0K | 211,675 |
| Mar 17, 2022 | Carter Laura | Chief Scientific Officer | Sell | 5,002 | $8.28 | $41.4K | 90,304 |
| Mar 17, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 6,279 | $8.28 | $52.0K | 66,172 |
| Oct 26, 2021 | Aranda Richard | Chief Medical Officer | Sell | 2,377 | $12.25 | $29.1K | 217,432 |
| Oct 26, 2021 | Carter Laura | Chief Scientific Officer | Sell | 2,377 | $12.25 | $29.1K | 95,306 |
| Oct 26, 2021 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 2,377 | $12.25 | $29.1K | 72,451 |
| Mar 25, 2021 | Christian Waage | EVP & General Counsel | Sell | 5,490 | $9.48 | $52.1K | 588,199 |
| Mar 25, 2021 | Giraudo Bryan | Chief Financial Officer | Sell | 5,490 | $9.48 | $52.0K | 109,889 |
| Mar 25, 2021 | Salter-Cid Luisa | Chief Scientific Officer | Sell | 5,491 | $9.48 | $52.1K | 206,065 |
GOSS Insider Buying Activity
The following table shows recent insider purchases of Gossamer Bio, Inc. (GOSS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 20, 2025 | Milligan Sandra | Director | Buy | 26,050 | $1.92 | $50.0K | 58,050+81% |
| Jun 24, 2024 | Hasnain Faheem | President & CEO | Buy | 372,000 | $0.67 | $250.3K | 5,408,073 |
| Jun 20, 2024 | Giraudo Bryan | COO/CFO | Buy | 100,000 | $0.59 | $59.1K | 480,010+26% |
| Jun 20, 2024 | Smith Robert Paul JR | Chief Commercial Officer | Buy | 25,000 | $0.60 | $15.1K | 25,000 |
| Nov 17, 2023 | Milligan Sandra | Director | Buy | 32,000 | $0.79 | $25.2K | 32,000 |
| Nov 14, 2023 | Giraudo Bryan | COO/CFO | Buy | 200,000 | $0.56 | $112.9K | 380,010+111% |
| Apr 5, 2023 | Giraudo Bryan | COO/CFO | Buy | 55,000 | $1.02 | $56.1K | 125,990+77% |
| Mar 22, 2023 | Christian Waage | EVP, Tech Ops and Admin | Buy | 18,500 | $1.20 | $22.1K | 32,388+133% |
| Mar 22, 2023 | Giraudo Bryan | COO/CFO | Buy | 50,000 | $0.97 | $48.4K | 70,990+238% |
| Mar 22, 2023 | Hasnain Faheem | President & CEO | Buy | 878,572 | $1.14 | $1.00M | 4,495,897 |
| Jul 15, 2022 | Carter Laura | Chief Scientific Officer | Buy | 6,934 | $7.21 | $50.0K | 87,168 |
| Jul 15, 2022 | Christian Waage | EVP, Tech Ops and Admin | Buy | 6,934 | $7.21 | $50.0K | 13,888+100% |
| Jul 15, 2022 | Giraudo Bryan | COO/CFO | Buy | 13,869 | $7.21 | $100.0K | 20,990+195% |
| Jul 15, 2022 | Hasnain Faheem | President & CEO | Buy | 138,696 | $7.21 | $1000.0K | 3,617,325 |
GOSS Insider Selling Activity
The following table shows recent insider sales of Gossamer Bio, Inc. (GOSS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 25, 2024 | Aranda Richard | Chief Medical Officer | Sell | 1,908 | $0.66 | $1.3K | 196,891 |
| Mar 28, 2024 | Christian Waage | EVP, Tech Ops and Admin | Sell | 6,430 | $1.16 | $7.4K | 585,934 |
| Mar 28, 2024 | Giraudo Bryan | COO/CFO | Sell | 6,430 | $1.16 | $7.4K | 92,737 |
| Mar 28, 2024 | Hasnain Faheem | President & CEO | Sell | 23,172 | $1.16 | $26.8K | 120,293 |
| Mar 19, 2024 | Aranda Richard | Chief Medical Officer | Sell | 4,018 | $1.33 | $5.3K | 198,799 |
| Mar 19, 2024 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,018 | $1.33 | $5.3K | 49,833 |
| Jun 26, 2023 | Aranda Richard | Chief Medical Officer | Sell | 1,814 | $1.29 | $2.3K | 197,574 |
| Mar 20, 2023 | Aranda Richard | Chief Medical Officer | Sell | 7,563 | $1.10 | $8.3K | 199,388 |
| Mar 20, 2023 | Carter Laura | Chief Scientific Officer | Sell | 6,029 | $1.10 | $6.6K | 76,263 |
| Mar 20, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 7,564 | $1.10 | $8.3K | 53,851 |
| Oct 25, 2022 | Aranda Richard | Chief Medical Officer | Sell | 4,757 | $12.07 | $57.4K | 205,430 |
| Oct 25, 2022 | Carter Laura | Chief Scientific Officer | Sell | 4,876 | $12.07 | $58.9K | 82,292 |
| Oct 25, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 4,757 | $12.07 | $57.4K | 61,415 |
| Jul 5, 2022 | Carter Laura | Chief Scientific Officer | Sell | 8,808 | $8.25 | $72.6K | 80,234 |
| Jun 23, 2022 | Aranda Richard | Chief Medical Officer | Sell | 1,778 | $6.88 | $12.2K | 209,897 |
| May 5, 2022 | Carter Laura | Chief Scientific Officer | Sell | 1,262 | $7.20 | $9.1K | 89,042 |
| Mar 24, 2022 | Giraudo Bryan | COO/CFO | Sell | 10,722 | $8.91 | $95.6K | 99,167 |
| Mar 24, 2022 | Christian Waage | EVP, Tech Ops and Admin | Sell | 10,722 | $8.91 | $95.6K | 579,008 |
| Mar 24, 2022 | Hasnain Faheem | President & CEO | Sell | 19,035 | $8.91 | $169.7K | 143,465 |
| Mar 17, 2022 | Aranda Richard | Chief Medical Officer | Sell | 6,278 | $8.28 | $52.0K | 211,675 |
| Mar 17, 2022 | Carter Laura | Chief Scientific Officer | Sell | 5,002 | $8.28 | $41.4K | 90,304 |
| Mar 17, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 6,279 | $8.28 | $52.0K | 66,172 |
| Oct 26, 2021 | Aranda Richard | Chief Medical Officer | Sell | 2,377 | $12.25 | $29.1K | 217,432 |
| Oct 26, 2021 | Carter Laura | Chief Scientific Officer | Sell | 2,377 | $12.25 | $29.1K | 95,306 |
| Oct 26, 2021 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 2,377 | $12.25 | $29.1K | 72,451 |
| Mar 25, 2021 | Christian Waage | EVP & General Counsel | Sell | 5,490 | $9.48 | $52.1K | 588,199 |
| Mar 25, 2021 | Giraudo Bryan | Chief Financial Officer | Sell | 5,490 | $9.48 | $52.0K | 109,889 |
| Mar 25, 2021 | Salter-Cid Luisa | Chief Scientific Officer | Sell | 5,491 | $9.48 | $52.1K | 206,065 |
GOSS Insiders
Similar Stocks to GOSS
VRTX
Vertex Pharmaceuticals Incorporated
$431.59-0.55%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$641.79+1.88%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$293.36-0.32%
$39.18B
RVMD
Revolution Medicines, Inc.
$151.45+2.82%
$31.78B
INSM
Insmed Incorporated
$107.56+0.37%
$25.06B
UTHR
United Therapeutics Corporation
$571.33+0.80%
$24.13B
ROIV
Roivant Sciences Ltd.
$32.10+13.82%
$20.96B
MRNA
Moderna, Inc.
$47.27+3.40%
$19.46B